DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Abou-Alfa GK, Blanc JF, Miles S. , et al.
Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma.
Oncologist 2017;
22 (07) 780-e65
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.